Author

A. Sboner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 8 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Assay:bulk RNA-seq· 6 Approach:experimental assay· 6 Research Focus:cell type annotation· 5 Research Focus:differential expression· 5 Research Focus:drug response / drug discovery· 4 Approach:statistical model· 3 Assay:whole-exome sequencing· 3

Frequent Co-Authors

J. M. Mosquera· 5 shared O. Elemento· 4 shared B. D. Robinson· 3 shared F. Khani· 3 shared H. Beltran· 3 shared J. Manohar· 3 shared R. Bareja· 3 shared A. Gopalan· 2 shared

Activity by Year

2020-2025 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

J. M. Mosquera

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Kinome focused CRISPR-Cas9 screens in African ancestry patient-derived breast cancer organoids identifies essential kinases and synergy of EGFR and FGFR1 inhibition.

F. P. Madorsky Rowdo, R. Martini, S. E. Ackermann, C. P. Tang, M. Tranquile, A. Irizarry, I. Us, O. Alawa, J. E. Moyer, M. Sigouros, J. Nguyen, M. A. Assaad, E. Cheng, P. S. Ginter, J. Manohar, , M. L. Martin

The paper uses CRISPR-Cas9 screens in breast cancer organoids from African ancestry patients to identify essential kinases and show synergy between EGFR and FGFR1 inhibitors.

Cancer Research · Feb 1, 2025Peer-reviewedCancer Biology

Canonical AREs are tumor suppressive regulatory elements in the prostate

M. A. Augello, X. Chen, D. Liu, K. Lin, A. Hakansson, M. Sjostrom, F. Khani, L. D. Deonarine, Y. Liu, J. Travascio-Green, J. Wu, M. Loda, F. Y. Feng, B. D. Robinson, E. Davicioni, , C. Barbieri

This study identifies canonical AREs as tumor suppressive regulatory elements in prostate cancer, showing their reactivation can induce death in AR+ cancer cells and is linked to better prognosis.

bioRxiv · Feb 23, 2024 · PreprintCancer Biology

Novel co-culture strategies of tumor organoids with autologous T-cells reveal clinically relevant combinations of immune-checkpoint and targeted therapies

E. Podaza, J. Capuano, M. Al Assaad, H.-h. Kuo, G. Markowitz, A. Irizarry, H. Ravichandran, S. Ackermann, T. Kane, J. Manohar, M. Sigouros, J. Moyer, B. Bhinder, P. Chandra, M. Malbari, , M. L. Martin

The paper develops co-culture strategies of tumor organoids with autologous T-cells to screen immune-checkpoint and targeted therapy combinations.

bioRxiv · Jul 5, 2023 · PreprintImmunology

Harbingers of Aggressive Prostate Cancer: Precision Oncology Case Studies

J. Cyrta, D. Prandi, A. Arora, D. H. Hovelson, A. Sboner, A. Rodriguez, T. Fedrizzi, H. Beltran, D. R. Robinson, A. Gopalan, L. True, P. Nelson, B. D. Robinson, J. M. Mosquera, S. Tomlins, , M. Rubin

This study identifies molecular features of primary prostate cancer and their relation to metastasis using genomic and histopathological analysis.

bioRxiv · Nov 30, 2021 · PreprintCancer Biology

The evolution of genomic, transcriptomic, and single-cell protein markers of metastatic upper tract urothelial carcinoma

K. Ohara, A. F. Rendeiro, B. Bhinder, K. W. Eng, H. Ravichandran, D. Pisapia, A. Vosoughi, E. Fernandez, K. Shohdy, J. Manohar, S. Beg, D. Wilkes, B. Robinson, F. Khani, R. Bareja, , J. M. Mosquera

The paper examines genomic, transcriptomic, and single-cell protein markers in metastatic upper tract urothelial carcinoma, finding discordant genomic alterations but stable molecular and immune subtypes between primary and metastatic tumors.

bioRxiv · Nov 16, 2021 · PreprintCancer Biology

SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape

I. Grbesa, M. A. Augello, D. Liu, D. R. McNally, C. D. Gaffney, D. Huang, K. Lin, R. Goueli, B. D. Robinson, F. Khani, L. D. Deonarine, M. Blattner, O. Elemento, E. Davicioni, A. Sboner, C. E. Barbieri

This study shows that SPOP mutations in prostate cancer alter the chromatin landscape and AR-driven transcription, making tumors more responsive to AR-targeted therapies.

bioRxiv · Apr 20, 2021 · PreprintCancer Biology

Patient-derived xenografts and organoids model therapy response in prostate cancer

S. Karkampouna, F. La Manna, M. R. De Filippo, M. Kiener, M. De Menna, E. Zoni, J. Grosjean, I. Klima, A. Garofoli, M. Bolis, J.-P. Theurillat, V. Genitsch, D. Keller, T. Booij, C. Stirnimann, , M. Kruithof-de Julio

This study develops a patient-derived xenograft (PDX) model of prostate cancer that mimics disease stages and identifies drug sensitivities in metastatic cases.

Nature Communications · Feb 18, 2021Peer-reviewedCancer Biology

Role of Specialized mSWI/SNF Complexes in Prostate Cancer Lineage Plasticity

J. Cyrta, A. Augspach, M. R. de Filippo, D. Prandi, P. Thienger, M. Benelli, V. Cooley, R. Bareja, D. Wilkes, S.-S. Chae, P. Cavaliere, N. Dephoure, A.-C. Uldry, S. B. Lagache, S. Cohen, , M. Rubin

The paper investigates the role of mSWI/SNF complexes in NEPC lineage plasticity using patient data and cell models, finding deregulated subunits and SMARCA4 overexpression linked to aggressive disease.

Nature Communications · Nov 3, 2020Peer-reviewedCancer Biology

Chromatin accessibility profiles of castration-resistant prostate cancers reveal novel subtypes and therapeutic vulnerabilities

F. Tang, S. Wang, C. K. Wong, C. J. Lee, S. Cohen, J. Park, C. E. Hill, K. Eng, R. Bareja, T. Han, E. M. Liu, A. Palladino, W. Di, D. Gao, W. Abida, , E. Khurana

This study identifies four subtypes of castration-resistant prostate cancer using ATAC-seq and RNA-seq data, revealing novel therapeutic targets and classification for 370 patients.

bioRxiv · Oct 26, 2020 · PreprintCancer Biology